期刊文献+

沙利度胺对子宫内膜异位症的内膜间质细胞体外表达VEGF的影响 被引量:4

Effects of thalidomide on vascular endothelial growth factors expression in endometrial stromal cells of endometriosis in vitro
下载PDF
导出
摘要 目的:观察沙利度胺(ThD)对子宫内膜异位症病人内膜间质细胞的增殖及其血管内皮生长因子(VEGF)表达的影响。方法:刮取子宫内膜异位症病人的子宫内膜组织,经体外分离、培养,用波形蛋白单抗进行免疫组化染色鉴定,应用四唑盐(MTS)分析肿瘤坏死因子α(TNF-α)和ThD对间质细胞生长的影响,以实时荧光定量PCR、Western Blot和定量ELISA分析在存在外源TNF-α的情况下,不同浓度ThD对间质细胞表达VEGF的影响。结果:TNF-α能促进子宫内膜间质细胞的增殖和分泌VEGF,而ThD能剂量依赖性抑制内膜间质细胞的增殖,并逆转TNF-α对VEGF的上调作用。结论:ThD可抑制体外培养的子宫内膜异位症内膜间质细胞的增殖及其VEGF的表达和分泌,提示ThD对于治疗子宫内膜异位症可能具有一定的作用。 AIM : To observe the effects of thalidomide (ThD) on cell proliferation and vascular endothelial growth factors (VEGF) expression in endometrial stromal cell of endometriosis in vitro. METHODS: Human endometrial tissue was obtained from patients with endometriosis. The stromal cells were isolated and identified by immunohistochemical staining with vimentin antibody. The influence of tumor necrosis factor-alpha (TNF-α) and ThD on proliferation of endometrial stromal cells was observed. The effects of different concentration of ThD on VEGF expression in endometrial stromal cells were analyzed by real-time PCR, Western Blot and ELISA. RESULTS: TNF-α could promote the proliferation of endometrial stromal cell and the secretion of VEGF, while ThD could inhibit the proliferation of endometrial stromal cell and reverse the up-regulation of VEGF expression by TNF-α. CONCLUSION: ThD could inhibit the proliferation of endometrial stromal cell and expression and secretion of VEGF in vitro, which suggested that ThD might have therapeutic effect on endometriosis.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2007年第9期641-645,共5页 Chinese Journal of New Drugs and Clinical Remedies
关键词 沙利度胺 子宫内膜异位症 体外研究 血管内皮生长因子 thalidomide endometriosis in vitro vascular endothelial growth factors
  • 相关文献

参考文献14

  • 1DONNEZ J,SMOES P,GILLEROT S,et al.Vascular endothelial growth factor (VEGF) in endometriosis[J].Hum Reprod,1998,13 (6):1686-1690.
  • 2NISOLLE M,CASANAS-ROUX F,DONNEZ J.Early-stage endometriosis:adhesion and growth of human menstrual encometriosis in nude mice[J].Fertil steril,2000,74(2):306-312.
  • 3顾彧,林金芳.单核细胞趋化蛋白1对子宫内膜间质细胞分泌血管内皮生长因子的影响[J].中华妇产科杂志,2004,39(3):187-189. 被引量:13
  • 4NEUFELD G,COHEN T,GENGRINOVITCH S,et al.Vascular endothelial growth factor(VEGF) and its receptors[J].FASEB J,1999,13(1):9-22.
  • 5SAKAMOTO Y,HARADA T,HORIE S,et al.Tumor necrosis factor-alpha-induced interleukin-8 (IL-8) expression in endometriotic stromal cells,probably through nuclear factor-kappa B activation:gonadotropin-releasing hormone agonist treatment reduced IL-8 expression[J].J Clin Endocrinol Metab,2003,88(2):730-735.
  • 6XAVIER P,BELO L,BEIRES J,et al.Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis[J].Arch Gynecol Obstet,2006,273(4):227-231.
  • 7ERIKSSON T,BJORKMAN S,HOGLUND P.Clinical pharmacology of thalidomide[J].Eur J Clin Pharmacol,2001,57 (5):365-376.
  • 8RAJKUMAR SV.Current status of thalidomide in the treatment of cancer[J].Oncology(Williston Park),2001,15(7):867-874.
  • 9夏志洁,许俊才.沙利度胺的老药新用[J].中国新药与临床杂志,2001,20(2):155-156. 被引量:7
  • 10刘玉胜,鹿庆华,马天容,蒋卫东,张华岩,王永梅,杜贻萌,徐冬玲,蒋乐.沙利度胺对慢性充血性心力衰竭的影响[J].中国新药与临床杂志,2006,25(10):734-736. 被引量:1

二级参考文献18

  • 1[1]Huaghes S, Nainggolan L. Products in 1997: Successes, setbacks and shocks in drug development[J]. Scrip Magazine,1998,50-89.
  • 2[2]Stirling DI. Thalidomide and the impact in dermatology[J]. Semin Cutan Med Surg,1998,17:231-242.
  • 3[3]Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma[J]. New Engl J Med,1999,341:1565-1571.
  • 4[4]Kneller A, Raanani P, Hardan I, et al. Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug[J]. Br J Haematol,2000,108:391-393.
  • 5[5]Yarchoan R. Therapy for Kaposi's sarcoma: recent advances and experimental approaches[J]. J Acquir Immune Defic Syndr, 1999,21 Suppl 1:S66-S73.
  • 6[6]Konno H, Tanaka T, Baba M, Kanai T, Nakamura S. Antiangiogenic therapy for liver metastasis of gastrointestinal malignancics[J]. J Hepatobiliary Pancreat Surg,1999,6:1-6.
  • 7[7]Mehta P, Kedar A, Graham-Pole J, Skoda-Smith S, Wingard J R. Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature. Pediatrics, 1999,103(4):e44.
  • 8[8]Hashimroto Y. Novel biological response modefiers derived from thalidomide[J]. Curr Med Chem,1998,5:163-178.
  • 9[9]McCarty MF. Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains:potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia and osteoporosis[J]. Med Hypotheses,1997,49:123-131.
  • 10[10]Lary JM, Daniel KL, Erickson JD, Roberts HE, Moore CA. The return of thalidomide: can birth defects be prevented?[J]. Drug Saf,1999,21:161-169.

共引文献18

同被引文献64

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部